Skip to main content

Andrew Benjamin Nixon

Professor in Medicine
Medicine, Medical Oncology

Selected Grants


Targeting Hepatocyte Senescence to Improve NAFLD

ResearchAdvisor · Awarded by National Institutes of Health · 2024 - 2029

Drug Development for Dystonia

ResearchCo Investigator · Awarded by Department of Defense · 2023 - 2027

Duke ACS Institutional Research Grant

ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026

The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2026

Targeting Hepatocyte Senescence to Improve NAFLD

ResearchAdvisor · Awarded by National Institutes of Health · 2024 - 2029

Drug Development for Dystonia

ResearchCo Investigator · Awarded by Department of Defense · 2023 - 2027

Duke ACS Institutional Research Grant

ResearchSignificant Contributor · Awarded by American Cancer Society, Inc. · 2024 - 2026

The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2026

IL-6 in PDIGREE (AO31704)

ResearchPrincipal Investigator · Awarded by Alliance for Clinical Trials in Oncology Foundation · 2020 - 2025

Circulating Protein Biomarker Analysis for women with HR-positive advanced breast cancer

ResearchPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2023 - 2025

A Randomized Phase 2 Trial to Evaluate Prebiotic Intervention in Allogeneic Hematopoietic Stem Cell Transplantation

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2025

Identification and validation of plasma-based protein biomarkers for cediranib and olaparib in GY005, phase III

ResearchPrincipal Investigator · Awarded by NRG Oncology · 2020 - 2024

A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

ResearchPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2021 - 2024

Clinical Biomarker Study of the Tumor NLRP3 Inflammasome and its Role in Anti-PD-1 Immunotherapy Resistance

ResearchCollaborator · Awarded by Conquer Cancer Foundation · 2021 - 2024

Brain Vasular Malformation Consortium: Predictors of clinical course

ResearchCo Investigator · Awarded by The Regents of the University of California · 2014 - 2024

Printed Electronic Biosensors for Point-of-Care Testing of Cardiovascular Biomarkers

ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2024

Immune signatures in metastatic colorectal cancer

ResearchPrincipal Investigator · Awarded by Genentech, Inc. · 2017 - 2023

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2014 - 2023

Single-cell cytokine profiling in metastatic colorectal cancer patients receiving immunotherapy

ResearchPrincipal Investigator · Awarded by Mario Family Foundation · 2022 - 2022

Home Transplant to Preserve the Microbiota and Decrease GVHD

ResearchCollaborator · Awarded by American Society of Hematology · 2019 - 2022

Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer

ResearchPartnering PI · Awarded by Department of Defense · 2018 - 2022

Plasma Angiome and Serum Androgens as Predictors of Overall Survival in Metastatic Prostate Cancer

ResearchPrincipal Investigator · Awarded by Department of Defense · 2018 - 2022

MSI in mCRC

ResearchPrincipal Investigator · Awarded by Promega · 2020 - 2022

Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions

ResearchCo Investigator · Awarded by Department of Defense · 2020 - 2022

The role of Claudin-2 in metastatic colorectal cancer

ResearchPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2016 - 2022

Blood-based Biomarker Profiling for TEW-7197

Clinical TrialPrincipal Investigator · Awarded by MedPacto, Inc · 2017 - 2021

Profiling the Adenosine Axis in Metastatic Colorectal Cancer

ResearchPrincipal Investigator · Awarded by MedImmune, Inc. · 2018 - 2021

AFT-42 Immune Cells

ResearchPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2019 - 2021

New strategies to improve drug development for carcinoid tumors

ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2019 - 2021

Pilot Study for Feasibility of Next Generation Sequencing for Detection of Lung Cancer ALK and ROS1 Mutation.

ResearchPrincipal Investigator · Awarded by HTG Molecular Diagnostics, Inc · 2019 - 2021

Angiome Profiling of GY012

ResearchPrincipal Investigator · Awarded by NRG Oncology · 2020 - 2021

Identification and validation of plasma-based protein biomarkers for cediranib and olaparib

ResearchPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2019 - 2020

Analysis of baseline blood samples from a clinical study evaluating TRC105 in metastatic renal cell carcinoma cancer patients

ResearchPrincipal Investigator · Awarded by Tracon Pharmaceuticals, Inc. · 2017 - 2019

Identification and validation of plasma-based protein biomarkers for cediranib and olaparib

ResearchPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2019 - 2019

Blood-based Biomarker Profiling for Regorafenib in Metastatic Colorectal Cancer

ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2017 - 2019

3D Biology Signatures defined by Nanostring Max System

EquipmentMajor User · Awarded by North Carolina Biotechnology Center · 2018 - 2019

Dovitinib in Treating Patients with Recurrent or Progressive Glioblastoma

ResearchPrincipal Investigator · Awarded by Cleveland Clinic Foundation · 2015 - 2018

Anti-Tumor Effects of locally and Systemically Administered EZN-2279 monotherapy in a murine model of Colorectal Carcinoma

ResearchPrincipal Investigator · Awarded by Leadiant Biosciences, Inc. · 2017 - 2018

Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer

ResearchCo Investigator · Awarded by American Association of Obstetricians and Gynecologists Foundation · 2017 - 2018

Blood-based Biomarker Profiling for TEW-7197

ResearchCo Investigator · Awarded by MedPacto, Inc · 2016 - 2018

Preclinical and Human Correlative Studies of a Novel Bruton Tyronsine Kinase Inhibitor in Pancreatic Cancer

ResearchCo Investigator · Awarded by Department of Defense · 2016 - 2017

CTOT - Cell Free DNA

ResearchPrincipal Investigator · Awarded by Mount Sinai School of Medicine · 2016 - 2017

Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling

ResearchCo Investigator · Awarded by National Institutes of Health · 2014 - 2017

Janssen Research AGreement

ResearchCo Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2016

The prevalence of MET gene amplification in metastatic colorectal cancer

ResearchPrincipal Investigator · Awarded by Amgen, Inc. · 2014 - 2016

Serum Biomarkers in Lymphoma

ResearchPrincipal Investigator · Awarded by Brigham and Women's Hospital · 2014 - 2015

(PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention'

ResearchCo Investigator · Awarded by National Institutes of Health · 2013 - 2014

Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity

ResearchCo Investigator · Awarded by National Institutes of Health · 2006 - 2012

New Clinical Biomarker for Cancer--Wound Angiogenesis

ResearchAssistant Research Professor · Awarded by National Institutes of Health · 2000 - 2006

Regulation Of Cyclic Gmp Phosphodiesterase By Gz

ResearchPI-Fellow · Awarded by National Institutes of Health · 1997 - 2001

External Relationships


  • Alliance for Clinical Trials in Oncology
  • Leap Therapeutics
  • NRG Oncology
  • National Cancer Intitute

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.